AN15368, an orally administered small-molecule precursor, undergoes activation by parasite carboxypeptidase, yielding a product that interferes with the messenger RNA processing pathway in T. cruzi. This compound shows promise for both preventing and investigating potential treatments for Chagas disease [1].